home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.66 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

May 07, 2024

From Beam Therapeutics

Via GlobeNewswire

Expert Ratings For Beam Therapeutics ↗

April 23, 2024

Via Benzinga

April 12, 2024

Via Benzinga

Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol ↗

April 02, 2024

Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with...

Via Benzinga

Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts ↗

March 27, 2024

Via Benzinga

Navigating 4 Analyst Ratings For Beam Therapeutics ↗

February 28, 2024

Via Benzinga

Recap: Beam Therapeutics Q4 Earnings ↗

February 27, 2024

Via Benzinga

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

March 26, 2024

Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024

From Beam Therapeutics

Via GlobeNewswire

MarketBeat Week in Review – 3/4 – 3/8

March 09, 2024

The market rally continues as the February Jobs Report reignited the soft landing talk, but momentum could stall if next week's inflation readings come in hot

Via MarketBeat

Topics Artificial Intelligence Economy

Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments

March 06, 2024

Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place

Via MarketBeat

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

February 28, 2024

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat ↗

February 27, 2024

Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.

Via Investor's Business Daily

Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug ↗

February 27, 2024

Both companies are working on treatments for genetic disorders.

Via Investor's Business Daily

Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday ↗

February 27, 2024

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

Via Benzinga

Topics Stocks

Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 27, 2024

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

Via Benzinga

Beam Therapeutics Inc. (NASDAQ: BEAM) Leading the Way in Tuesday Trading Based on Percentage Gain

February 27, 2024

Via Investor Brand Network

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

February 27, 2024

From Beam Therapeutics

Via GlobeNewswire

Is CRISPR Therapeutics the NVIDIA of gene editing?

February 26, 2024

CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv

Via MarketBeat

Topics Artificial Intelligence

Beam Therapeutics Stock Shows Healthy Relative Strength Improvement ↗

February 16, 2024

In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday.

Via Investor's Business Daily

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Via MarketBeat

Topics Artificial Intelligence

Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss ↗

February 08, 2024

Via Benzinga

3 Biotech Stocks to Buy on the Dip: February 2024 ↗

February 07, 2024

Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities

Via InvestorPlace

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

February 05, 2024

From Beam Therapeutics

Via GlobeNewswire

Why Beam Therapeutics Stock Zoomed 17% Higher Today ↗

January 29, 2024

JPMorgan Chase becomes the latest institution in the company's bull pen.

Via The Motley Fool

2 gene editing stocks to keep on your 2024 watchlist

January 23, 2024

Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

Via MarketBeat

Bitcoin, Ethereum, Dogecoin Rise As Investors Weigh Spot ETF Impact: Analyst Says Scenario For King Crypto Is 'Rejection' At $46K And Then Correction To Below $40K ↗

January 16, 2024

Major cryptocurrencies on Tuesday evening posted some gains following a weekend characterized by

Via Benzinga

Topics ETFs

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market ↗

January 16, 2024

Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.

Via InvestorPlace

3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street ↗

January 16, 2024

Analysts have high hopes for these three innovation companies in 2024.

Via The Motley Fool

3 Stocks to Buy in the Booming Field of Gene Editing ↗

January 11, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

Via InvestorPlace

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

January 08, 2024

From Beam Therapeutics

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com